RXRB and neoplasm: It is noteworthy that, in addition to the amplification of ERBB2, QIAGEN Clinical Insight® identified “likely pathogenic” mutations in PRDM2 (PR domain zinc finger protein 2; c.3259C>T; [17, 18]), RXRB (retinoid X receptor beta; c.1174C>T), TPR (translocated promoter region, nuclear basket protein; c.6955C>T), and ZNF845 (zinc finger protein 845; c.1831A>T) from 2891 mutations shared in the three lesions (Figs. 3c and 4a), which corroborates the hypothesis that these lesions originated from the same tumor cells.